IDH2 and acute myeloid leukemia: Future molecules such as the hedgehog signaling pathway inhibitor, glasdegib, two IDH inhibitors, ivosidenib (IDH1 inhibitor) and enasidenib (IDH2 inhibitor), the fully absorbable oral formulation of the hypomethylating agent decitabine and partially orally absorbable azacitidine will be, together with venetoclax, the expanding armamentarium against AML in the elderly [33].